Eli Lilly and Company (LLY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Eli Lilly and Company (LLY) is up 2.6% since the beginning of the year. At $1,099 per share, LLY is trading 7.1% below its 52-week high of $1,183. Investors who bought $1,000 worth of LLY shares 5 years ago would now be looking at an investment worth $5,270.

Eli Lilly and Company (LLY) has returned 2.57% so far this year and 45.05% over the past 12 months. Looking at the last ten years, LLY has achieved an annualized return of 33.23%, outperforming the S&P 500 Index benchmark, which averaged 13.54% per year.

Based on dividend-adjusted daily data since Jan 13, 1978, LLY's average daily return is +0.07%, while the average monthly return is +1.51%. At this rate, an investment would double in approximately 3.9 years.

Historically, 57% of months were positive and 43% were negative. The best month was Jun 2000 with a return of +30.7%, while the worst month was Aug 2000 at -29.5%. The longest winning streak lasted 13 consecutive months, and the longest losing streak was 6 months.

On a daily basis, LLY closed higher 50% of trading days. The best single day was Jun 29, 2000 with a return of +16.5%, while the worst single day was Aug 9, 2000 at -29.1%.

Eli Lilly and Company has an annualized alpha of 10.85%, beta of 0.79, and R2 of 0.25 versus S&P 500 Index. Calculated based on daily prices since January 13, 1978.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (87.40%) than losses (52.83%) - typical of diversified or defensive assets.
• R2 of 0.25 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

LLY ranks 72 for risk / return — better than 72% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

Eli Lilly and Company provided a 0.59% dividend yield over the last twelve months, with an annual payout of $6.46 per share. The company has been increasing its dividends for 27 consecutive years, earning it the status of a dividend aristocrat.

The table displays the monthly dividend distributions for Eli Lilly and Company. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Eli Lilly and Company. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Eli Lilly and Company was 68.24%, occurring on Mar 5, 2009. Recovery took 1425 trading sessions.

The current Eli Lilly and Company drawdown is 5.37%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Eli Lilly and Company over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Eli Lilly and Company is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.